A hastening of the review process by about 3.6 years to 1 year represents an reduction by 71% of wait time: a dramatic technological improvement (or reduction of waste) accessible to the pharmaceutical industry, holding quality of drug constant.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment